Akebia Therapeutics Inc. (NASDAQ:AKBA) price on Thursday, April 18, remained unchanged to $1.39.
A look at the stock’s price movement, the close in the last trading session was $1.39. The beta value (5-Year monthly) was 0.84. Turning to its 52-week performance, $2.48 and $0.59 were the 52-week high and 52-week low respectively. Overall, AKBA moved -24.04% over the past month.
Akebia Therapeutics Inc.’s market cap currently stands at around $291.02 million, with investors looking forward to this quarter’s earnings report slated for May 06, 2024 – May 10, 2024.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that AKBA is a 50% Buy. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
AKBA’s current price about -18.07% and -13.56% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 39.53, while 7-day volatility ratio is 6.61% and 10.76% in the 30-day chart. Further, Akebia Therapeutics Inc. (AKBA) has a beta value of 0.91, and an average true range (ATR) of 0.15.
If we refocus on Akebia Therapeutics Inc. (NASDAQ:AKBA), historical trading data shows that trading volumes averaged 4.79 million over the past 3 months. The company’s latest data on shares outstanding shows there are 194.58 million shares.
The 10.84% of Akebia Therapeutics Inc.’s shares are in the hands of company insiders while institutional holders own 18.45% of the company’s shares. Current price change has pushed the stock 12.10% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the AKBA stock continues to rise going into the next quarter.
